がん用バイオマーカーの世界市場予測（～2022年）：タンパク質バイオマーカー、遺伝子バイオマーカー...市場調査レポートについてご紹介

【英文タイトル】Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要（一部）】

TABLE OF CONTENTS

1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.2.1 MARKETS COVERED 24
1.2.2 YEARS CONSIDERED FOR THE STUDY 24
1.3 CURRENCY 25
1.4 LIMITATIONS 25
1.5 STAKEHOLDERS 25

2 RESEARCH METHODOLOGY 26
2.1 MARKET SIZE ESTIMATION 27
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 30
2.2.1 SECONDARY SOURCES 31
2.2.1.1 Key Industry Insights 32
2.3 ASSUMPTIONS FOR THE STUDY 33

3 EXECUTIVE SUMMARY 34

4 PREMIUM INSIGHTS 38
4.1 CANCER BIOMARKERS: MARKET SNAPSHOT 38
4.2 ASIA PACIFIC CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY AND APPLICATION 39
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2017 VS. 2022 40
4.4 CANCER BIOMARKERS MARKET SHARE, BY BIOMARKER TYPE, 2015 TO 2022 40
4.5 CANCER BIOMARKERS MARKET, BY REGION 41

5 MARKET OVERVIEW 42
5.1 INTRODUCTION 42
5.1.1 DRIVERS 43
5.1.1.1 Technological advancements 43
5.1.1.2 Rising incidence of cancer 43
5.1.1.3 Increasing use of cancer biomarkers in drug discovery and development 44
5.1.1.4 Increasing research on cancer biomarkers 44
5.1.2 RESTRAINTS 45
5.1.2.1 Unfavorable regulatory and reimbursement scenario 45
5.1.2.2 High capital investment and low benefit-cost ratio 45
5.1.2.3 Technical issues related to sample collection and storage 46
 
5.1.3 OPPORTUNITIES 46
5.1.3.1 Personalized medicine 46
5.1.3.2 Companion diagnostics 46
5.1.3.3 Emerging economies 47
5.1.4 CHALLENGES 47
5.1.4.1 Proving the clinical validity and utility of biomarker-based tests 47

6 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE 48
6.1 INTRODUCTION 49
6.2 PROTEIN BIOMARKERS 50
6.3 GENETIC BIOMARKERS 52
6.3.1 LUNG CANCER 54
6.3.2 COLORECTAL CANCER 56
6.3.3 BREAST CANCER 57
6.3.4 PROSTATE CANCER 58
6.3.5 LEUKEMIA 59
6.4 OTHER CANCER BIOMARKERS 60

7 CANCER BIOMARKER MARKET, BY CANCER TYPE 63
7.1 INTRODUCTION 64
7.2 BREAST CANCER 65
7.3 LUNG CANCER 68
7.4 COLORECTAL CANCER 70
7.5 PROSTATE CANCER 72
7.6 NON-HODGKIN’S LYMPHOMA 74
7.7 MELANOMA 76
7.8 LEUKEMIA 78
7.9 THYROID CANCER 80
7.10 BLADDER CANCER 82
7.11 KIDNEY CANCER 84
7.12 OTHER CANCER TYPES 86

8 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY 89
8.1 INTRODUCTION 90
8.1.1 OMICS TECHNOLOGIES 91
8.1.2 PROTEOMICS 94
8.1.3 GENOMICS 96
8.1.3.1 Next-generation sequencing (NGS) 98
8.1.3.2 Polymerase chain reaction (PCR) 101
8.1.4 OTHER OMICS TECHNOLOGIES 103
 
8.2 IMAGING TECHNOLOGIES 106
8.2.1 ULTRASOUND 108
8.2.2 COMPUTED TOMOGRAPHY (CT) 110
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 113
8.2.4 POSITRON EMISSION TOMOGRAPHY (PET) 115
8.2.5 MAMMOGRAPHY 117
8.3 IMMUNOASSAYS 119
8.4 CYTOGENETICS 123
8.4.1 IN SITU HYBRIDIZATION (ISH) 125
8.4.2 OTHER CYTOGENETICS-BASED TESTS 128
8.5 BIOINFORMATICS 130

9 CANCER BIOMARKERS MARKET, BY APPLICATION 133
9.1 INTRODUCTION 134
9.2 DIAGNOSTICS 135
9.3 RESEARCH AND DEVELOPMENT 137
9.4 PROGNOSTICS 139
9.5 RISK ASSESSMENT 141
9.6 OTHER APPLICATIONS 143

10 CANCER BIOMARKERS MARKET, BY REGION 146
10.1 INTRODUCTION 147
10.2 NORTH AMERICA 148
10.2.1 US 153
10.2.2 CANADA 157
10.3 EUROPE 161
10.3.1 GERMANY 166
10.3.2 UK 170
10.3.3 FRANCE 174
10.3.4 ITALY 178
10.3.5 SPAIN 182
10.3.6 REST OF EUROPE (ROE) 186
10.4 ASIA PACIFIC 190
10.4.1 JAPAN 195
10.4.2 REST OF APAC 199
10.5 REST OF THE WORLD (ROW) 203

11 COMPETITIVE LANDSCAPE 208
11.1 MARKET RANKING ANALYSIS, 2016 208
 

12 COMPANY PROFILES 209
(BUSINESS OVERVIEW, PRODUCTS OFFERED, STRENGTH OF PRODUCT PORTFOLIO, BUSINESS STRATEGY EXCELLENCE, RECENT DEVELOPMENTS.)*
12.1 THERMO FISHER SCIENTIFIC 209
12.2 BIO-RAD LABORATORIES 212
12.3 ROCHE DIAGNOSTICS 215
12.4 QIAGEN N.V. 218
12.5 ILLUMINA 222
12.6 GE HEALTHCARE 225
12.7 AGILENT TECHNOLOGIES 228
12.8 BIOMÉRIEUX SA 231
12.9 MERCK & CO. 234
12.10 ABBOTT LABORATORIES 237
12.11 BECTON, DICKINSON AND COMPANY 240
12.12 DANAHER CORPORATION 242
12.13 MYRIAD GENETICS 245
12.14 SYSMEX CORPORATION 248
12.15 HOLOGIC 251
12.16 QUEST DIAGNOSTICS 254
*Details on Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key relationships might not be captured in case of unlisted companies.

13 APPENDIX 257
13.1 INSIGHTS OF INDUSTRY EXPERTS 257
13.2 DISCUSSION GUIDE 258
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 262
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 264
13.5 AVAILABLE CUSTOMIZATIONS 266
13.6 RELATED REPORTS 266
13.7 AUTHOR DETAILS 267

【レポート販売概要】

■ タイトル：がん用バイオマーカーの世界市場予測（～2022年）：タンパク質バイオマーカー、遺伝子バイオマーカー
■ 英文：Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022
■ 発行日：2017年10月5日
■ 調査会社：MarketsandMarkets
■ 商品コード：MAM-MD-5627
■ 調査対象地域：グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業（メーカー、ベンダー）、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。

Follow:

RSS [PRニュース]